Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06800092 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

Study acronym: SPARC
StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Mar 15, 2026 to Jun 15, 2027v6
  2. Start date: Oct 15, 2025 to Mar 15, 2026
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v5
  3. Start date: Jun 15, 2025 to Oct 15, 2025v4
  4. Start date: May 15, 2025 to Jun 15, 2025v3
  5. Start date: Feb 15, 2025 to May 15, 2025v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
Trial Details
NCT Number NCT06800092
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions
(from sponsor)		 Cancer
Related terms Fatigue, Mental Fatigue, Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov